Abstract 1671P
Background
The rise of the internet has transformed communication and healthcare, allowing easy access to sensitive medical test results. However, this practice lacks regulation. Breast cancer, the most common cancer in women, has seen improved survival rates, leading to more individuals living with the disease. Patients accessing their results online can pose challenges for oncologists due to the anxiety stemming from this constant access. Studies show conflicting outcomes regarding the emotional impact of this access, ranging from increased patient engagement to heightened anxiety. This study aims to investigate whether online receipt of sensitive results can worsen the emotional health of oncology patients, for instance, by intensifying anxiety symptoms.
Methods
This cross-sectional study employed a questionnaire with four sections to assess patients diagnosed with breast cancer within five years. The questionnaire covered demographic information, online test result access habits, anxiety levels during result anticipation, and validated screening tools for personality disorders (PID-5-BF), anxiety (GAD-7), and depression (PHQ-9). Sample size estimation for confidence interval calculations targeted 385 patients. The current analysis includes data from 198 respondents.
Results
Among the 198 participants, 196 (99%) were female, with only 2 (1%) being male. The majority (75.3%) received their breast cancer diagnosis within the past 1 to 5 years. In terms of cancer staging, 41.4% had early-stage disease (Stages I-III), while 57.6% had advanced-stage disease (Stage IV). Concerning online result access, 25.3% reported infrequent online result checks, while 74.2% confirmed habitual checking. During result anticipation, 64.6% expressed anxiety, primarily described as mild (62.2%). Statistical analyses indicated no significant association between online result access behavior and anxiety levels (p=0.609), anxiety disorders (p=0.411), or depressive disorders (p=0.484).
Conclusions
This interim analysis did not reveal a correlation between receiving potentially sensitive test results online and patient anxiety. Recruitment is ongoing and on target to produce a final analysis in the near future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1656TiP - The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)
Presenter: Sarah Howlett
Session: Poster session 11
1658TiP - The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)
Presenter: Minal Padden-Modi
Session: Poster session 11
1659TiP - A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
Presenter: Mark Stein
Session: Poster session 11
1660TiP - First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Raanan Berger
Session: Poster session 11
1661TiP - SEGNO: An exploratory study of the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer
Presenter: Haichao Huang
Session: Poster session 11
1662TiP - HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)
Presenter: Qian Qin
Session: Poster session 11
1664P - Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes
Presenter: Niharika Bisht
Session: Poster session 11
1665P - Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
Presenter: Raffaela Sartori
Session: Poster session 11